Byron Capital Healthcare and Biotech analyst Douglas Loe says OncoGenex Pharmaceuticals’ (NASDAQ:OGXI) OGX-427 is the most under appreciated drug in Canadian biotech.
Loe says the clinical pipeline for OGX-427 is large and is growing, including a whopping eight Phase II oncology clinical trials. Four of these trials, he says are sizable, randomized and controlled studies from which credible insights will soon be available. Loe says this asset is often overshadowed by OncoGenex’s own OGX-011, a treatment designed to block the production of clusterin, a cell-survival protein that is over-produced in several malignancies and in response to many cancer treatments.
Loe says OGX-011 accounts for much of the value many attain to the company, so investors buying OncoGenex are getting the potential blockbuster that is OGX-427 essentially for free. In a research update to clients this morning, Loe maintained his BUY rating and $30.50 target on Oncogenex.